Article
Endocrinology & Metabolism
Chin-Hsiao Tseng
Summary: This study examined the risk of prostate cancer in diabetes patients who had used or never used rosiglitazone in Taiwan. Male patients with a new diagnosis of type 2 diabetes mellitus were selected from the nationwide database of the National Health Insurance and followed up for prostate cancer incidence. The results showed that there was no significant association between rosiglitazone use and prostate cancer risk.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Review
Medicine, General & Internal
Rita R. Kalyani
Summary: Individualized glycemic targets, along with comprehensive reduction in cardiovascular risk factors, are essential in managing type 2 diabetes to reduce both microvascular and macrovascular complications. Glucose-lowering medications with demonstrated cardiovascular benefits, such as GLP-1 receptor agonists or SGLT2 inhibitors, are recommended for patients with established cardiovascular disease or at high risk for cardiovascular events.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Endocrinology & Metabolism
Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park
Summary: Lobeglitazone showed a tendency to improve albuminuria in patients with T2DM and had comparable effects on albuminuria as pioglitazone, demonstrating similar efficacy in treating albuminuria.
Article
Multidisciplinary Sciences
Chao-Chung Ho, Yi-Sun Yang, Chien-Ning Huang, Shih-Chang Lo, Yu-Hsun Wang, Edy Kornelius
Summary: This study evaluated the renal-protective effects of pioglitazone in diabetic kidney disease patients. The results showed that pioglitazone did not reduce the risk of renal disease progression in these patients. Further randomized controlled studies are needed to establish the effects of pioglitazone definitively.
Article
Endocrinology & Metabolism
Pradip Mukhopadhyay, Debmalya Sanyal, Purushottam Chatterjee, Kaushik Pandit, Sujoy Ghosh
Summary: Recent recommendations for SGLT2 inhibitors in the management of type 2 diabetes are primarily based on their ability to reduce cardiovascular adverse events, particularly cardiovascular death. However, their effect on reducing myocardial infarction and stroke events has not been well explored.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Article
Cardiac & Cardiovascular Systems
David D. Berg, Filipe A. Moura, Andrea Bellavia, Benjamin M. Scirica, Stephen D. Wiviott, Deepak L. Bhatt, Itamar Raz, Erin A. Bohula, Robert P. Giugliano, Jeong-Gun Park, Mark W. Feinberg, Eugene Braunwald, David A. Morrow, Marc S. Sabatine
Summary: A risk model for atherothrombosis in patients with type 2 diabetes mellitus (T2DM) was developed and validated using data from 42,181 patients. The model identified 16 independent predictors of myocardial infarction (MI) or ischemic stroke (IS). The model performed well in validation and has the potential to improve risk assessment and clinical decision-making.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Dae Young Cheon, Kyungdo Han, Ye Seul Yang, Yerim Kim, Sang-Hwa Lee, Chulho Kim, Jong-Hee Sohn, Mi Sun Oh, Byung-Chul Lee, Minwoo Lee, Kyung-Ho Yu
Summary: This study found a significant association between migraines and major cardiovascular events, including myocardial infarction, ischemic stroke, and cardiovascular death, in individuals with type 2 diabetes. The presence of aura symptoms in migraines further increased the risk of myocardial infarction.
CARDIOVASCULAR DIABETOLOGY
(2022)
Review
Endocrinology & Metabolism
David S. H. Bell, Terri Jerkins
Summary: Pioglitazone improves glycaemic control by enhancing beta cell function and reducing insulin resistance. It also has positive effects on cardiac risk factors and cardiovascular disease, lowering the incidence of cardiac events in diabetic patients. Pioglitazone is effective in reducing the recurrence of transient ischaemic attack and ischaemic stroke in non-diabetic, insulin-resistant subjects. Additionally, it improves diastolic function in heart failure patients and decreases the incidence of atrial fibrillation through atrial remodelling suppression. Pioglitazone also shows potential in improving insulin resistance-related diseases, such as non-alcoholic steatohepatitis and polycystic ovary disease, as well as dermatopathies like psoriasis. However, biases from the toxicities of other thiazolidinediones have led to underutilization of pioglitazone.
DIABETES OBESITY & METABOLISM
(2023)
Review
Biochemistry & Molecular Biology
Cristina Rey-Renones, Jose Miguel Baena-Diez, Isabel Aguilar-Palacio, Cristina Miquel, Maria Grau
Summary: Individuals with type 2 diabetes are at higher risk for developing and dying from cancer, possibly due to metabolic abnormalities such as obesity. Understanding this link can aid in designing personalized preventive strategies.
Article
Medicine, General & Internal
Yong Hoon Kim, Ae-Young Her, Myung Ho Jeong, Byeong-Keuk Kim, Sung-Jin Hong, Seunghwan Kim, Chul-Min Ahn, Jung -Sun Kim, Young-Guk Ko, Donghoon Choi, Myeong-Ki Hong, Yangsoo Jang
Summary: Current smoking has negative effects on the clinical outcomes of prediabetic and AMI patients, highlighting the need for increased attention and more intensive treatment strategies including smoking cessation.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES
(2022)
Article
Cardiac & Cardiovascular Systems
Yue Gao, Hua-yan Xu, Ying-kun Guo, Xiao-ling Wen, Rui Shi, Yuan Li, Zhi-gang Yang
Summary: The study found that myocardial scarring size in T2DM patients after MI is negatively correlated with LV global PS and PSSR, particularly in the circumferential direction. Different MI regions have different effects on the reduction of LV deformation, and relevant clinical evaluations should be strengthened.
CARDIOVASCULAR DIABETOLOGY
(2021)
Article
Endocrinology & Metabolism
Yiwen Cui, Astrid Marshall, Shirng-Wern Tsaih, Anna Palatnik
Summary: This study found that women with a history of GDM and T2DM are more prone to macrovascular complications, including myocardial infarction and coronary artery disease.
JOURNAL OF DIABETES AND ITS COMPLICATIONS
(2022)
Review
Endocrinology & Metabolism
Jaehyun Bae, Taegyun Park, Hyeyoung Kim, Minyoung Lee, Bong-Soo Cha
Summary: Lobeglitazone, a novel TZD, provides potent glycemic efficacy, low effective dose, and favorable safety results, with pleiotropic effects in preclinical and clinical studies. This drug was developed to address the demands for an effective and safe TZD in treating Type 2 diabetes mellitus.
DIABETES & METABOLISM JOURNAL
(2021)
Article
Chemistry, Medicinal
Jingwen Liu, Xiaoye Li, Hong Wang, Yan Ren, Yiming Li, Fujiang Guo
Summary: Researchers identified a selective PPARγ modulator called Bavachinin (BVC), which effectively regulates bone homeostasis and shows potential for the prevention and treatment of diabetes. The prodrug of BVC (BN) improves water solubility, absorption, and circulation time.
PHYTOTHERAPY RESEARCH
(2023)
Article
Cardiac & Cardiovascular Systems
John Hung, Andreas Roos, Erik Kadesjo, David A. McAllister, Dorien M. Kimenai, Anoop S. Shah, Atul Anand, Fiona E. Strachan, Keith A. A. Fox, Nicholas L. Mills, Andrew R. Chapman, Martin J. Holzmann
Summary: The GRACE 2.0 score showed good discrimination for predicting all-cause death at 1 year in patients with type 1 myocardial infarction, but only moderate discrimination for those with type 2 myocardial infarction.
EUROPEAN HEART JOURNAL
(2021)